Ali Mossaid, MD
Internal Medicine · E Providence, RINPI 1316508278
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 299 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,594, more than ten times the $199 reported in 2022. Among internal medicine clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 299 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$838
- Lilly USA, LLC$762
- AstraZeneca$562
- Pfizer$524
- Boehringer Ingelheim$428
- plus $2K from 20 others
What the payments were for
- Food & beverage$6,304100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 53 | $1,058 |
| AbbVie | 45 | $838 |
| Lilly USA, LLC | 32 | $762 |
| AstraZeneca | 28 | $562 |
| Pfizer | 27 | $524 |
| Boehringer Ingelheim | 15 | $428 |
| GSK | 21 | $404 |
| Idorsia Pharmaceuticals US Inc | 9 | $259 |
| Exact Sciences | 13 | $254 |
| Ardelyx, Inc. | 7 | $208 |
| Sumitomo Pharma America, Inc. | 8 | $176 |
| Merck | 6 | $109 |
| Shield Therapeutics Inc | 6 | $106 |
| Rigel Pharmaceuticals, Inc. | 4 | $101 |
| E.r. Squibb & Sons, L.L.C. | 5 | $95 |
| Johnson & Johnson(2 entities) | 4 | $92 |
| Phathom Pharmaceuticals, Inc. | 4 | $76 |
| Abbott | 2 | $48 |
| Viatris Specialty LLC | 2 | $44 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Amgen | 1 | $32 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Mylan Specialty L.p. | 1 | $24 |
| Verona Pharma, Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,324 in reported general payments places this provider in the 95th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 85 | $70,733 |
| JardianceEmpagliflozin | 47 | $41,734 |
| XareltoRivaroxaban | 28 | $28,094 |
| RybelsusSemaglutide | 18 | $26,054 |
| JanuviaSitagliptin Phosphate | 21 | $20,431 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $19,046 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $11,905 |
| LinzessLinaclotide | 16 | $8,135 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $7,675 |
| Posaconazole | 14 | $7,317 |
| Atorvastatin Calcium | 436 | $5,697 |
| Esomeprazole Magnesium | 44 | $5,416 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $5,187 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,133 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 190 | $4,950 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $524 | $70,73385 claims |
| Boehringer IngelheimJardiance | $428 | $41,73447 claims |
| MerckJanuvia, Janumet | $109 | $32,33637 claims |
| Johnson & JohnsonXarelto | $92 | $28,09428 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $404 | $26,72251 claims |
| Novo NordiskRybelsus | $1,058 | $26,05418 claims |
| AbbVieLinzess | $838 | $8,13516 claims |
| AstraZenecaSymbicort | $562 | $5,13316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in E Providence
- Elham MohammadiradE Providence$4K
- Anthony RochaE Providence$4K
- William BeliveauJohnson$951K
- Katarzyna Gilek-SeibertProvidence$131K
- Randall InghamProvidence$100K
- Frank D'alessandroLincoln$93K
- Gregory AllenCranston$38K
- Richard RuggieriProvidence$30K
- Gerry OvideProvidence$29K
- Todd ViccioneEast Greenwich$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.